SAR348830
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581028

CAS#: 1462949-64-9

Description: SAR348830 is novel potent and selective inhibitor of anaplastic lymphoma kinase (ALK).

Chemical Structure

img
SAR348830
CAS# 1462949-64-9
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 581028
Name: SAR348830
CAS#: 1462949-64-9
Chemical Formula: C28H32FN5O3S
Exact Mass: 537.22
Molecular Weight: 537.650
Elemental Analysis: C, 62.55; H, 6.00; F, 3.53; N, 13.03; O, 8.93; S, 5.96

Price and Availability

Size Price Availability Quantity
10mg USD 150
25mg USD 250
50mg USD 450
100mg USD 750
200mg USD 1250
500mg USD 2650 2 Weeks
1g USD 3750 2 Weeks
2g USD 6450 2 Weeks
Bulk inquiry

Synonym: SAR348830; SAR 348830; SAR-348830.

IUPAC/Chemical Name: 7-(5-Fluoro-2-methoxyphenyl)-2-[[2-(1-methylethoxy)-4-(4-methyl-1-piperazinyl)phenyl]amino]-thieno[3,2-d]pyrimidine-6-methanol

InChi Key: SWRGFJBGNAEJOY-UHFFFAOYSA-N

InChi Code: InChI=1S/C28H32FN5O3S/c1-17(2)37-23-14-19(34-11-9-33(3)10-12-34)6-7-21(23)31-28-30-15-24-27(32-28)26(25(16-35)38-24)20-13-18(29)5-8-22(20)36-4/h5-8,13-15,17,35H,9-12,16H2,1-4H3,(H,30,31,32)

SMILES Code: OCC1=C(C2=CC(F)=CC=C2OC)C3=NC(NC4=CC=C(N5CCN(C)CC5)C=C4OC(C)C)=NC=C3S1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: SAR348830 is an ALK inhibitor.
In vitro activity: To be determined
In vivo activity: To be determined

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 100.0 185.99

Preparing Stock Solutions

The following data is based on the product molecular weight 537.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: To be determined
In vitro protocol: To be determined
In vivo protocol: To be determined

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Oya Y, Yoshida T, Kuroda H, Shimizu J, Horio Y, Sakao Y, Hida T, Yatabe Y. Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure. Anticancer Res. 2017 Nov;37(11):6477-6480. PubMed PMID: 29061835.

2: Geller S, Canavan TN, Pulitzer M, Moskowitz AJ, Myskowski PL. ALK-positive primary cutaneous anaplastic large cell lymphoma: a case report and review of the literature. Int J Dermatol. 2017 Oct 23. doi: 10.1111/ijd.13804. [Epub ahead of print] Review. PubMed PMID: 29057463.

3: West H. Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs. Ann Transl Med. 2017 Sep;5(18):371. doi: 10.21037/atm.2017.08.29. Review. PubMed PMID: 29057231; PubMed Central PMCID: PMC5635256.

4: Leberfinger AN, Behar BJ, Williams NC, Rakszawski KL, Potochny JD, Mackay DR, Ravnic DJ. Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Systematic Review. JAMA Surg. 2017 Oct 18. doi: 10.1001/jamasurg.2017.4026. [Epub ahead of print] PubMed PMID: 29049466.

5: Yoshida R, Sasaki T, Minami Y, Hibino Y, Okumura S, Sado M, Miyokawa N, Hayashi S, Kitada M, Ohsaki Y. Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer. Int J Oncol. 2017 Sep 28. doi: 10.3892/ijo.2017.4140. [Epub ahead of print] PubMed PMID: 29048652.

6: Zeng L, Kang R, Zhu S, Wang X, Cao L, Wang H, Billiar TR, Jiang J, Tang D. ALK is a therapeutic target for lethal sepsis. Sci Transl Med. 2017 Oct 18;9(412). pii: eaan5689. doi: 10.1126/scitranslmed.aan5689. PubMed PMID: 29046432.

7: Dolgikh N, Fulda S. Rhabdomyosarcoma cells are susceptible to cell death by LDK378 alone or in combination with sorafenib independently of anaplastic lymphoma kinase status. Anticancer Drugs. 2017 Nov;28(10):1118-1125. doi: 10.1097/CAD.0000000000000552. PubMed PMID: 29045271.

8: Werner MT, Zhang Q, Wasik MA. From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL). Cancers (Basel). 2017 Oct 16;9(10). pii: E138. doi: 10.3390/cancers9100138. Review. PubMed PMID: 29035291.

9: Iijima-Yamashita Y, Mori T, Nakazawa A, Fukano R, Takimoto T, Tsurusawa M, Kobayashi R, Horibe K. Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma. Int J Hematol. 2017 Oct 13. doi: 10.1007/s12185-017-2338-6. [Epub ahead of print] PubMed PMID: 29030834.

10: Ryu S, Hayashi M, Aikawa H, Okamoto I, Fujiwara Y, Hamada A. Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionisation mass spectrometry imaging: A pilot study. Br J Pharmacol. 2017 Oct 13. doi: 10.1111/bph.14067. [Epub ahead of print] PubMed PMID: 29027209.

11: Oyama Y, Nishida H, Kusaba T, Kadowaki H, Arakane M, Daa T, Watanabe D, Akita Y, Sato F, Mimata H, Yokoyama S. A case of anaplastic lymphoma kinase-positive renal cell carcinoma coincident with Hodgkin lymphoma. Pathol Int. 2017 Oct 12. doi: 10.1111/pin.12592. [Epub ahead of print] PubMed PMID: 29024210.

12: Chaudhari N, Talwar P, Lefebvre D'hellencourt C, Ravanan P. CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells. Front Mol Neurosci. 2017 Sep 26;10:310. doi: 10.3389/fnmol.2017.00310. eCollection 2017. PubMed PMID: 29018329; PubMed Central PMCID: PMC5623017.

13: Kuenzi BM, Remsing Rix LL, Stewart PA, Fang B, Kinose F, Bryant AT, Boyle TA, Koomen JM, Haura EB, Rix U. Polypharmacology-based ceritinib repurposing using integrated functional proteomics. Nat Chem Biol. 2017 Oct 9. doi: 10.1038/nchembio.2489. [Epub ahead of print] PubMed PMID: 28991240.

14: Muller IB, de Langen AJ, Giovannetti E, Peters GJ. Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. Onco Targets Ther. 2017 Sep 13;10:4535-4541. doi: 10.2147/OTT.S109493. eCollection 2017. Review. PubMed PMID: 28979145; PubMed Central PMCID: PMC5602476.

15: Saiki M, Ohyanagi F, Ariyasu R, Koyama J, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Horiike A, Ninomiya H, Ishikawa Y, Nishio M. Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene. Jpn J Clin Oncol. 2017 Sep 18:1-4. doi: 10.1093/jjco/hyx133. [Epub ahead of print] PubMed PMID: 28977547.

16: Kwatra KS, Paul PAM, Calton N, John JM, Cotelingam JD. Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile. South Asian J Cancer. 2017 Jul-Sep;6(3):129-131. doi: 10.4103/2278-330X.214575. PubMed PMID: 28975123; PubMed Central PMCID: PMC5615884.

17: Vendrell JA, Taviaux S, Béganton B, Godreuil S, Audran P, Grand D, Clermont E, Serre I, Szablewski V, Coopman P, Mazières J, Costes V, Pujol JL, Brousset P, Rouquette I, Solassol J. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. Sci Rep. 2017 Oct 2;7(1):12510. doi: 10.1038/s41598-017-12679-8. PubMed PMID: 28970558; PubMed Central PMCID: PMC5624911.

18: Wu D, Liu L, Yan X, Wang C, Wang Y, Han K, Lin S, Gan Z, Min D. Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein. Oncotarget. 2017 Jul 10;8(38):63857-63870. doi: 10.18632/oncotarget.19148. eCollection 2017 Sep 8. PubMed PMID: 28969035; PubMed Central PMCID: PMC5609967.

19: Otsuki Y, Saya H, Arima Y. Prospects for new lung cancer treatments that target EMT signaling. Dev Dyn. 2017 Sep 27. doi: 10.1002/dvdy.24596. [Epub ahead of print] Review. PubMed PMID: 28960588.

20: Takeuchi S, Murayama T, Yoshimura K, Kawakami T, Takahara S, Imai Y, Kuribayashi Y, Nagase K, Goto K, Nishio M, Hasegawa Y, Satouchi M, Kiura K, Seto T, Yano S. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol. J Med Invest. 2017;64(3.4):317-320. doi: 10.2152/jmi.64.317. PubMed PMID: 28955006.